Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Durex licenses VivaGel

This article was originally published in The Tan Sheet

Executive Summary

SSL International, the manufacturer of Durex brand condoms, signs a licensing agreement with Starpharma Holdings for marketing rights to a condomcoated with Starpharma's VivaGel, a vaginal microbicide gel under development for the prevention of sexually transmitted infections, including genital herpes and HIV infection, the firms announce Sept. 9. The deal secures SSL the rights to market a VivaGel coated condom in most markets, including Europe and the U.S., and Starpharma estimates it will receive more than $100 million from SSL for royalties on sales, further milestone payments and developmental support, Melbourne, Australia-based Starpharma says. The firm also continues to develop VivaGel as an applicator-delivered vaginal microbicide for women to protect against STIs

You may also be interested in...

Pulling In 10 Different Directions – The Challenge Of Harmonizing Asia’s VMS Market

A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.

China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.

Coronavirus Update: J&J’s Single Shot Could Catch Up With Frontrunners

Company is confident that data readout from pivotal trial could be ready before the end of 2020.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts